Gemvax & Kael

This study looked at the long-term safety of a drug called GV1001 in people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and balance. 67 patients who had already completed a previous GV1001 trial received daily injections for another 12 mo…

This study tested an experimental drug called GV1001 in 199 people with mild to moderate Alzheimer's disease. The drug is given as a shot under the skin and aims to protect brain cells and improve memory. Researchers measured changes in thinking and daily living skills over 52 we…

This study tested a drug called GV1001 in 78 people with Progressive Supranuclear Palsy (PSP), a rare brain disease that affects movement and thinking. Participants received daily injections of either a low dose, a high dose, or a placebo for 6 months. The goal was to see if the …

This early-stage study tested the safety of a drug called GV1001 in 59 healthy adults aged 19 to 50. Participants received either a single dose or multiple doses of the drug or a placebo. The goal was to check for side effects and how the drug moves through the body, not to treat…